Pulsatile delivery of a leucine supplement during long-term continuous enteral feeding enhances lean growth in term neonatal pigs

Am J Physiol Endocrinol Metab. 2016 Apr 15;310(8):E699-E713. doi: 10.1152/ajpendo.00479.2015. Epub 2016 Feb 16.

Abstract

Neonatal pigs are used as a model to study and optimize the clinical treatment of infants who are unable to maintain oral feeding. Using this model, we have shown previously that pulsatile administration of leucine during continuous feeding over 24 h via orogastric tube enhanced protein synthesis in skeletal muscle compared with continuous feeding alone. To determine the long-term effects of leucine pulses, neonatal piglets (n = 11-12/group) were continuously fed formula via orogastric tube for 21 days, with an additional parenteral infusion of either leucine (CON + LEU; 800 μmol·kg-1·h-1) or alanine (CON + ALA) for 1 h every 4 h. The results show that body and muscle weights and lean gain were ∼25% greater, and fat gain was 48% lower in CON + LEU than CON + ALA; weights of other tissues were unaffected by treatment. Fractional protein synthesis rates in longissimus dorsi, gastrocnemius, and soleus muscles were ∼30% higher in CON + LEU compared with CON + ALA and were associated with decreased Deptor abundance and increased mTORC1, mTORC2, 4E-BP1, and S6K1 phosphorylation, SNAT2 abundance, and association of eIF4E with eIF4G and RagC with mTOR. There were no treatment effects on PKB, eIF2α, eEF2, or PRAS40 phosphorylation, Rheb, SLC38A9, v-ATPase, LAMTOR1, LAMTOR2, RagA, RagC, and LAT1 abundance, the proportion of polysomes to nonpolysomes, or the proportion of mRNAs encoding rpS4 or rpS8 associated with polysomes. Our results demonstrate that pulsatile delivery of a leucine supplement during 21 days of continuous enteral feeding enhances lean growth by stimulating the mTORC1-dependent translation initiation pathway, leading to protein synthesis in skeletal muscle of neonates.

Keywords: growth; infant; leucine; orogastric feeding; protein metabolism.

MeSH terms

  • Alanine / pharmacology
  • Amino Acid Transport System A / drug effects
  • Amino Acid Transport System A / metabolism
  • Animals
  • Animals, Newborn
  • Back Muscles
  • Dietary Supplements
  • Enteral Nutrition
  • Infusions, Parenteral
  • Leucine / administration & dosage
  • Leucine / pharmacology*
  • Mechanistic Target of Rapamycin Complex 1
  • Mechanistic Target of Rapamycin Complex 2
  • Multiprotein Complexes / drug effects
  • Multiprotein Complexes / metabolism
  • Muscle Proteins / drug effects*
  • Muscle Proteins / metabolism
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / metabolism
  • Phosphorylation / drug effects
  • Protein Biosynthesis / drug effects*
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Ribosomal Protein S6 Kinases, 90-kDa / drug effects
  • Ribosomal Protein S6 Kinases, 90-kDa / metabolism
  • Ribosomal Proteins / drug effects
  • Ribosomal Proteins / genetics
  • Sus scrofa
  • Swine
  • TOR Serine-Threonine Kinases / drug effects
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Amino Acid Transport System A
  • Multiprotein Complexes
  • Muscle Proteins
  • RNA, Messenger
  • Ribosomal Proteins
  • ribosomal protein S4
  • ribosomal protein S8
  • Mechanistic Target of Rapamycin Complex 1
  • Mechanistic Target of Rapamycin Complex 2
  • Ribosomal Protein S6 Kinases, 90-kDa
  • TOR Serine-Threonine Kinases
  • Leucine
  • Alanine